En DE FR ES PL
Hirabezol - instructions for use, reviews, analogs and formulations (tablets 10 mg and 20 mg) drugs for the treatment of ulcers, GERD, Helicobacter, Zollinger-Ellison syndrome in adults, children and pregnancy. Composition

Hirabezol - instructions for use, reviews, analogs and formulations (tablets 10 mg and 20 mg) drugs for the treatment of ulcers, GERD, Helicobacter, Zollinger-Ellison syndrome in adults, children and pregnancy. Composition

In this article, you can read the instructions for using the drug Hirabesol. There are reviews of visitors to the site - consumers of this medication, as well as opinions of doctors of specialists on the use of hirabesol in their practice. A big request is to actively add their feedback on the drug: the medicine helped or did not help get rid of the disease, which were observed complications and side effects, possibly not declared by the manufacturer in the annotation. Analogues of hirabesol in the presence of existing structural analogues. Use for the treatment of stomach and duodenal ulcers, including Helicobacter,gastroesophageal reflux disease or GERD, Zollinger-Ellison syndrome in adults, children, as well as during pregnancy and lactation. Composition of the preparation.

 

Hirabesol - Antiulcer from the group of proton pump inhibitors (N / K-ATPase), is metabolized in parietal cells of the stomach to active sulfonamide derivatives that inactivate the sulfhydryl groups of H / K-ATPase.

 

It blocks the final stage of the secretion of hydrochloric acid, reducing the content of basal and stimulated secretion, regardless of the nature of the stimulus.

 

It has a high lipophilicity, easily penetrates into the parietal cells of the stomach and concentrates in them, providing a cytoprotective effect.

 

The antisecretory effect after oral administration of 20 mg occurs within 1 hour and reaches a maximum after 2-4 hours; depression of basal and stimulated food of acid secretion through 23 hours after the first intake is 62% and 82%, respectively; the duration of action is 48 hours. After the end of the reception, the secretory activity is normalized within 2-3 days.

 

In the first 2-8 weeks of therapy, the concentration of gastrin in the serum increases and returns to baseline levels in1-2 weeks after discontinuation of the drug. Does not affect the central nervous system, cardiovascular and respiratory systems.

 

Composition

 

Rabeprazole sodium + excipients.

 

Pharmacokinetics

 

Absorbed from the small intestine (due to the presence of an acid-resistant enteric-soluble coat). Absorption is high, the time to reach Cmax is 3.5 hours. Bioavailability is 52%, it does not increase with multiple admission. The connection with plasma proteins is 97%. Metabolised in the liver with the participation of cytochrome P450 isoenzymes (CYP 2C19 and CYP 3A4). It is excreted by the kidneys - 90% in the form of two metabolites: a conjugate of mercapturic acid (M5) and carboxylic acid (M6); intestine - 10%.

 

Indications

  • peptic ulcer of the stomach and duodenum in the stage of exacerbation;
  • gastroesophageal reflux disease;
  • hypersecretory conditions, including Zollinger-Ellison syndrome;
  • Stress ulcers of the digestive tract.

 

As part of complex therapy:

  • eradication of Helicobacter pylori (Helicobacter) in patients with peptic ulcer of stomach and duodenum or chronic gastritis;
  • treatment and prevention of recurrence of peptic ulcer associated with Helicobacter pylori.

 

Forms of release

 

Tablets coated with enteric coating 10 mg and 20 mg.

 

Instructions for use and reception scheme

 

The drug is prescribed 20 mg once a day. Tablets should be taken orally, in the morning before meals, swallowing whole, without chewing or grinding.

 

With duodenal ulcer and gastric ulcer in the acute stage, 20 mg (1 tablet) is prescribed once a day in the morning for 4-6 weeks.

 

In gastroesophageal reflux disease (GERD), 20 mg (1 tablet) is prescribed once a day for 4-8 weeks.

 

For maintenance therapy with GERD - in a dose of 10 or 20 mg once a day, depending on the patient's response.

 

For symptomatic treatment of GERD in patients without esophagitis - in a dose of 10 mg 1 time per day for 4 weeks.

 

For the treatment of Zollinger-Ellison syndrome and other conditions characterized by pathological hypersecretion, the dose is selected individually.

 

For the treatment of duodenal ulcer or chronic gastritis associated with infection with Helicobacter pylori, a course of treatment of 7 days with one of the following combinations of drugs is recommended:

  1. Hyrabezole 20 mg twice a day + clarithromycin 500 mg twice a day and amoxicillin 1 g 2 times a day.
  2. Hairabesol 20 mg twice a day + clarithromycin 500 mg twice a day and metronidazole 400 mg twice a day.

 

Side effect

  • diarrhea, constipation;
  • nausea, vomiting;
  • abdominal pain;
  • flatulence;
  • dry mouth;
  • eructation;
  • dyspepsia;
  • a violation of taste sensations;
  • anorexia;
  • stomatitis;
  • gastritis;
  • increased transaminase activity;
  • headache;
  • dizziness;
  • asthenia;
  • insomnia;
  • nervousness;
  • drowsiness;
  • depression;
  • visual impairment;
  • violation of taste;
  • myalgia;
  • arthralgia;
  • cramps of the calf muscles;
  • inflammation or infection of the upper respiratory tract;
  • coughing;
  • sinusitis;
  • bronchitis;
  • thrombocytopenia, leukopenia;
  • leukocytosis;
  • rash;
  • itching;
  • pain in the back, chest, limbs;
  • edema;
  • urinary tract infection;
  • fever;
  • chills;
  • influenza-like syndrome;
  • increased sweating;
  • increase in body weight.

 

Contraindications

  • pregnancy;
  • breast-feeding;
  • children and adolescents under 18;
  • hypersensitivity to rabeprazole, benzimidazoles or other components of the drug.

 

Application in pregnancy and lactation

 

Hirabezol should not be prescribed during pregnancy (there is no safety data for the use of Rabeprazole in pregnancy).

 

It is not known whether rabeprazole is excreted in breast milk.Appropriate studies in lactating women were not conducted. For the duration of treatment, breastfeeding should be discontinued.

 

Use in children

 

The drug is contraindicated in children and adolescents under the age of 18 (there is no experience with the use of hirabesol in pediatric practice).

 

special instructions

 

Before and after treatment with hirabesol, endoscopic control is necessary to exclude malignant neoplasm since treatment can mask symptoms and delay correct diagnosis.

 

It is advisable to use caution in the first appointment of rabeprazole to patients with severe impairment of liver function.

 

The drug has no effect on thyroid function, carbohydrate metabolism, parathyroid hormone, cortisol, estrogen, testosterone, prolactin, cholecystokinin, secretin, glucagon, follicle stimulating hormone, luteinizing hormone, renin, aldosterone and growth hormone.

 

Patients with impaired renal or hepatic function do not need a dose adjustment.

 

The withdrawal of the drug is not accompanied by a rebound phenomenon, the recovery of secretory activity occurs within 2-3 days as the synthesis of new enzyme molecules.

 

Impact on the ability to drive vehicles and manage mechanisms

 

In the case of the appearance of drowsiness during the treatment should be abandoned from driving and other activities that require increased concentration and speed of psychomotor reactions.

 

Drug Interactions

 

Hirabezol slows the excretion of certain drugs metabolized in the liver by microsomal oxidation (diazepam, phenytoin, indirect anticoagulants).

 

Reduces the concentration of Ketoconazole by 33%, Digoxin by 22%.

 

Does not interact with liquid antacids.

 

Compatible with drugs metabolized by the CYP 450 system (warfarin, phenytoin, theophylline, diazepam).

 

Analogues of the drug Hyabrezole

 

Structural analogs for the active substance:

  • Beret;
  • Zolispan;
  • Zulbeks;
  • Нофлюкс;
  • Ontime;
  • Parries;
  • Rabelock;
  • Rabeprazole;
  • Rabeprazole sodium;
  • Reason.

 

Analogues for the pharmacological group (proton pump inhibitors):

  • Acrylase;
  • Vimovo;
  • Gastrozole;
  • Dexylant;
  • Demeprazole;
  • Zhelezolic;
  • A zerocide;
  • Zipantola;
  • Zolser;
  • Controllers;
  • Chrismel;
  • Crosatide;
  • Lanzabel;
  • Lanzap;
  • Lansoptol;
  • Lansoprazole;
  • Lansofed;
  • Lancid;
  • Losek;
  • Loenzar sanovel;
  • Nexium;
  • Nolpaz;
  • Omesol;
  • Omez;
  • Omez D;
  • Omez Insta;
  • Omeprazole;
  • Omepros;
  • Omeface;
  • Omizak;
  • OmiPix;
  • Omitox;
  • Ortanol;
  • Ozid;
  • Pantaz;
  • Pantoprazole Canon;
  • Pepazol;
  • Pepticum;
  • Pylobact;
  • Pylobakt AM;
  • Pomez;
  • Puloreph;
  • Romesque;
  • Sunpras;
  • Ulzol;
  • Ulcozol;
  • Ulter;
  • Ultop;
  • Helithrix;
  • Helicid;
  • Helol;
  • Cisagast;
  • Esomeprazole;
  • Emanera;
  • Epicurus.

Similar medicines:

Other medicines:

Reviews (3):
Guests
Alsou
Advantages of hirabesol: The maintenance of the minimum amount of carbohydrates allows prescribing the drug to patients with diabetes mellitus.
Guests
Lilia Viktorovna
Khayrabezol, the content of the minimum amount of carbohydrates allows prescribing the drug to patients with diabetes mellitus - Approved by the Ministry of Health of the Russian Federation, 15-02-2017.
Khayrabezol is innovative in its way, as a specially developed complex of auxiliary substances, in contrast to the reference preparation or analogues in the world.
Administrators
admin
Lilia Viktorovna and the rest, For the first time I stand a warning Your advertising campaign for advertising Hyabrezole in reviews under the guise of ordinary visitors. If such a policy continues, a more serious punishment will follow - all those noted by such customized reviews will be banned with a loss of opportunity to comment, the drug will be added to the local blacklist, and the moderation of comments to it is significantly tightened.

Rules for publishing reviews and visitor questions